Should cardiovascular disease prevention be undertaken by politicians?GRECO, Donato; LAURENDI, Giovanna.Dialogues in cardiovascular medicine. 2009, Vol 14, Num 2, pp 112-118, issn 1272-9949, 7 p.Article

Risk Communication Recommendations and Implementation During Emerging Infectious Diseases: A Case Study of the 2009 H1N1 Influenza PandemicGESSER-EDELSBURG, Anat; MORDINI, Emilio; JAMES, James J et al.Disaster medicine and public health preparedness. 2014, Vol 8, Num 2, pp 158-169, issn 1935-7893, 12 p.Article

Antibody kinetics and long-term sero-prevalence in the Italian clinical trial of acellular pertussis vaccinesGIULIANO, M; MASTRANTONIO, P; GIAMMANCO, A et al.Developments in biological standardization. 1997, Num 89, pp 275-278, issn 0301-5149Conference Paper

Methods for estimating serological correlates of protectionSIBER, G. R.Developments in biological standardization. 1997, Num 89, pp 283-296, issn 0301-5149Conference Paper

Preparation and composition of acellular pertussis vaccines. Consideration of potential effects on vaccine efficacyHEWLETT, E. L.Developments in biological standardization. 1997, Num 89, pp 143-151, issn 0301-5149Conference Paper

A comparison of enzyme immuno-assays used to measure serum antibodies to components of Bordetella pertussisLYNN, F; REED, G. F; MEADE, B. D et al.Developments in biological standardization. 1997, Num 89, pp 197-204, issn 0301-5149Conference Paper

Common side effects in the Italian and Stockholm I trialsTOZZI, A. E; OLIN, P.Developments in biological standardization. 1997, Num 89, pp 105-108, issn 0301-5149Conference Paper

Comparison of serological results in the NIAID multicenter acellular pertussis trial with recent efficacy trialsEDWARDS, K. M; DECKER, M. D.Developments in biological standardization. 1997, Num 89, pp 265-273, issn 0301-5149Conference Paper

European union research strategies on vaccinesHANSEN, B.Developments in biological standardization. 1997, Num 89, pp 29-36, issn 0301-5149Conference Paper

Examination of similarities between diphtheria and pertussis and their toxoids provide insight into vaccine-induced protection to Bordetella pertussisSCHNEERSON, R; ROBBINS, J. B; TARANGER, J et al.Developments in biological standardization. 1997, Num 89, pp 321-326, issn 0301-5149Conference Paper

Implications of different study designs for the evaluation of acellular pertussis vaccinesFINE, P. E. M.Developments in biological standardization. 1997, Num 89, pp 123-133, issn 0301-5149Conference Paper

Issues regarding future research on pertussis vaccinesBURNS, D.Developments in biological standardization. 1997, Num 89, issn 0301-5149, p.377Conference Paper

Regulatory issues concerning pertussis vaccinesTIRU, M.Developments in biological standardization. 1997, Num 89, issn 0301-5149, p.341Conference Paper

Some thoughts for future pertussis research in EuropePLETSCHETTE, M.Developments in biological standardization. 1997, Num 89, issn 0301-5149, p.391Conference Paper

A consideration of control requirements for acellular pertussis vaccinesCORBEL, M. J; XING, D. K. L.Developments in biological standardization. 1997, Num 89, pp 343-347, issn 0301-5149Conference Paper

Absolute efficacy of acellular pertussis vaccines in household settingsSTORSAETER, J; GUSTAFSSON, L.Developments in biological standardization. 1997, Num 89, pp 153-158, issn 0301-5149Conference Paper

Adverse reactions of a pertussis toxoid vaccine in a double-blind placebo-controlled trialTARANGER, J; TROLLFORS, B; KNUTSSON, N et al.Developments in biological standardization. 1997, Num 89, pp 109-112, issn 0301-5149Conference Paper

Are serological responses to acellular pertussis antigens sufficient criteria to ensure that new combination vaccines are effective for prevention of disease?GRANOFF, D. M; RAPPUOLI, R.Developments in biological standardization. 1997, Num 89, pp 379-389, issn 0301-5149Conference Paper

Bordetella pertussis-specific Th1/Th2 cells generated following respiratory infection or immunization with an acellular vaccine : Comparison of the T cell cytokine profiles in infants and miceRYAN, M; GOTHEFORS, L; STORSAETER, J et al.Developments in biological standardization. 1997, Num 89, pp 297-305, issn 0301-5149Conference Paper

Factors influencing the analysis of secondary prevention of pertussisWIRSING VON KÖNIG, C. H; SCHMITT, H. J; BOGAERTS, H et al.Developments in biological standardization. 1997, Num 89, pp 175-179, issn 0301-5149Conference Paper

Safety evaluation of one whole-cell and three acellular pertussis vaccines in Stockholm trial IIHEIJBEL, H; RASMUSSEN, F; OLIN, P et al.Developments in biological standardization. 1997, Num 89, pp 99-100, issn 0301-5149Conference Paper

The effectiveness of whole-cell pertussis vaccinesPLOTKIN, S. A.Developments in biological standardization. 1997, Num 89, pp 171-174, issn 0301-5149Conference Paper

Bordetella pertussis serotype of clinical isolates in Sweden during 1970-1995 and influence of vaccine efficacy studiesTIRU, M; ASKELÖF, P; GRANSTRÖM, M et al.Developments in biological standardization. 1997, Num 89, pp 239-245, issn 0301-5149Conference Paper

Diagnostic pertussis serology in the recent clinical efficacy studies of acellular vaccinesHALLANDER, H. O.Developments in biological standardization. 1997, Num 89, pp 205-212, issn 0301-5149Conference Paper

Differences by antigen in seroconversion : Sensitivity, specificity and bias in the serological confirmation of pertussisWASSILAK, S. G. F; ANEMONA, A; GIULIANO, M et al.Developments in biological standardization. 1997, Num 89, pp 221-228, issn 0301-5149Conference Paper